Patents by Inventor Dieter Kadereit

Dieter Kadereit has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Piperidinyl-substituted isoquinolone derivatives
    Patent number: 8188117
    Abstract: The invention relates to 6-piperidinyl-substituted isoquinolone derivatives of the formula (I) or isoquinoline derivatives of the formula (I?) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.
    Type: Grant
    Filed: January 25, 2008
    Date of Patent: May 29, 2012
    Assignee: Sanofi-Aventis
    Inventors: Oliver Plettenburg, Armin Hofmeister, Dieter Kadereit, Joachim Brendel, Matthias Loehn
  • CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES
    Publication number: 20110251226
    Abstract: The invention relates to 6-cyclohexylamine-substituted isoquinolone derivatives of the formula (I) or isoquinoline derivatives of the formula (I?) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.
    Type: Application
    Filed: June 15, 2011
    Publication date: October 13, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Oliver Plettenburg, Armin Hofmeister, Dieter Kadereit, Stefan Peukert, Sven Ruf, Kurt Ritter, Matthias Loehn, Yuri Ivashchenko, Peter Monecke, Matthias Dreyer, Aimo Kannt
  • ISOQUINOLINE DERIVATIVES
    Publication number: 20110245248
    Abstract: The invention relates to 6-piperidinyl-substituted isoquinoline derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.
    Type: Application
    Filed: June 15, 2011
    Publication date: October 6, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Oliver Plettenburg, Armin Hofmeister, Dieter Kadereit, Stefan Peukert, Sven Ruf, Kurt Ritter, Matthias Loehn, Yuri Ivashchenko, Peter Monecke, Matthias Dreyer, Aimo Kannt
  • OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS
    Publication number: 20110190490
    Abstract: The present invention relates to oxazolopyrimidine compounds of the formula I in which A, R1, R2 and R3 are defined as indicated in the claims. The compounds of the formula I modulate the activity of the Edg-1 receptor and in particular are agonists of this receptor, and are useful for the treatment of diseases such as atherosclerosis, heart failure or peripheral arterial occlusive disease, for example. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: July 2, 2009
    Publication date: August 4, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Dieter Kadereit, Matthias Schaefer, Werngard Czechtizky
  • ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS
    Publication number: 20110152290
    Abstract: The present invention relates to compounds of the formula I, wherein A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Application
    Filed: November 4, 2010
    Publication date: June 23, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Matthias SCHAEFER, Josef PERNERSTORFER, Dieter KADEREIT, Hartmut STROBEL, Werngard CZECHTIZKY, L. Charlie CHEN, Alena SAFAROVA, Aleksandra WEICHSEL, Marcel PATEK
  • Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments
    Patent number: 7781459
    Abstract: The invention relates to acyl-carboxyphenylurea derivatives and to their physiologically tolerated salts and physiologically functional derivatives. Compounds of the formula I, in which the radicals have the stated meanings, and the physiological tolerated salts thereof and processes for preparing them are described. The compounds are suitable for example for the treatment of type II diabetes.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: August 24, 2010
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Elisabeth DeFossa, Dieter Kadereit, Thomas Klabunde, Hans-Joerg Burger, Andreas Herling, Karl-Ulrich Wendt, Erich Von Roedern, Karl Schoenafinger, Alfons Enhsen
  • USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME
    Publication number: 20100144862
    Abstract: The invention relates to the use of substituted pyranone acid derivatives and of their physiologically acceptable salts for producing medicaments for treating the metabolic syndrome.
    Type: Application
    Filed: July 16, 2009
    Publication date: June 10, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Harm BRUMMERHOP, Siegfried STENGELIN, Hubert HEUER, Susanne KILP, Andreas HERLING, Thomas KLABUNDE, Dieter KADEREIT, Matthias URMANN
  • Cycloalkylamine substituted isoquinoline derivatives
    Publication number: 20100081671
    Abstract: The invention relates to 6-substituted isoquinoline derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.
    Type: Application
    Filed: June 18, 2009
    Publication date: April 1, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Oliver PLETTENBURG, Armin HOFMEISTER, Dieter KADEREIT, Stefan PEUKERT, Sven RUF, Matthias LÖHN, Peter MONECKE, Alexander SCHIFFER, Aimo KANNT, Markus KOHLMANN
  • Piperidinyl-substituted isoquinolone derivatives
    Publication number: 20090093518
    Abstract: The invention relates to 6-piperidinyl-substituted isoquinolone derivatives of the formula (I) or isoquinoline derivatives of the formula (I?) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.
    Type: Application
    Filed: January 25, 2008
    Publication date: April 9, 2009
    Applicant: SANOFI-AVENTIS
    Inventors: Oliver Plettenburg, Armin Hofmeister, Dieter Kadereit, Joachim Brendel, Matthias Loehn
  • Isoquinoline Derivatives
    Publication number: 20090088429
    Abstract: The invention relates to 6-piperidinyl-substituted isoquinoline derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.
    Type: Application
    Filed: December 20, 2007
    Publication date: April 2, 2009
    Applicant: SANOFI-AVENTIS
    Inventors: Oliver PLETTENBURG, Armin HOFMEISTER, Dieter KADEREIT, Stefan PEUKERT, Sven RUF, Kurt RITTER, Matthias LOEHN, Yuri IVASHCHENKO, Peter MONECKE, Matthias DREYER, Aimo KANNT
  • USE OF SUBSTITUTED CYCLOPROPANE ACID DERIVATIVES FOR PRODUCING DRUGS FOR USE IN THE TREATMENT OF METABOLIC SYNDROME
    Publication number: 20090088474
    Abstract: The present invention comprises methods for reducing plasma lipids, plasma free fatty acids (FFA), plasma glycerol and triglycerides in a mammal through the administration of certain substituted cyclopropane acid derivatives of Formula 1: wherein R1-R6 are defined herein and pharmaceutical compositions comprising them.
    Type: Application
    Filed: December 4, 2008
    Publication date: April 2, 2009
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Dieter Kadereit, Siegfried Stengelin, Hubert Heuer, Harm Brummerhop
  • Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
    Patent number: 7501440
    Abstract: The invention relates to compounds of the formula I where the radicals are as defined, and their physiologically tolerated salts. The compounds are suitable, for example, as medicaments for preventing and treating type 2 diabetes.
    Type: Grant
    Filed: March 8, 2004
    Date of Patent: March 10, 2009
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Karl Schoenafinger, Dieter Kadereit, Elisabeth Defossa, Andreas Herling, Thomas Klabunde
  • Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
    Patent number: 7498341
    Abstract: The invention relates to heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. The invention relates to compounds of the formula I in which the radicals have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example as medicaments for the prevention and treatment of type 2 diabetes.
    Type: Grant
    Filed: January 25, 2005
    Date of Patent: March 3, 2009
    Assignee: Sanofi Aventis Deutschland GmbH
    Inventors: Elisabeth Defossa, Dieter Kadereit, Sven Ruf, Thomas Klabunde, Dieter Schmoll, Andreas Herling, Karl-Ulrich Wendt
  • Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
    Patent number: 7470706
    Abstract: The invention relates to cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. The invention relates to compounds of the formula I in which the radicals have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example as medicaments for the prevention and treatment of type 2 diabetes.
    Type: Grant
    Filed: January 25, 2005
    Date of Patent: December 30, 2008
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Elisabeth Defossa, Dieter Kadereit, Thomas Klabunde, Dieter Schmoll, Andreas Herling, Karl-Ulrich Wendt, Sven Ruf
  • Cyclohexylamin isoquinolone derivatives
    Publication number: 20080242699
    Abstract: The invention relates to 6-cyclohexylamine-substituted isoquinolone derivatives of the formula (I) or isoquinoline derivatives of the formula (I?) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.
    Type: Application
    Filed: January 25, 2008
    Publication date: October 2, 2008
    Applicant: SANOFI-AVENTIS
    Inventors: Oliver PLETTENBURG, Armin HOFMEISTER, Dieter KADEREIT, Joachim BRENDEL, Matthias LOEHN
  • 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
    Patent number: 7402674
    Abstract: 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments The invention relates to 7-phenylamino-4-quinolone-3-carboxylic acid derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. The invention relates to compounds of the formula I in which the radicals have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example as medicaments for the prevention and treatment of type 2 diabetes.
    Type: Grant
    Filed: January 25, 2005
    Date of Patent: July 22, 2008
    Assignee: Sanofi-Aventis Deutschland GmbH,
    Inventors: Elisabeth Defossa, Dieter Kadereit, Sven Ruf, Thomas Klabunde, Dieter Schmoll, Andreas Herling, Karl-Ulrich Wendt
  • Substituted benzoylureido-o-benzoylamides, process for their preparation and their use
    Patent number: 7378440
    Abstract: The invention relates to substituted benzoylureido-o-benzoylamides and to their physiologically tolerated salts and physiologically functional derivatives. The invention relates to compounds of the formula I in which the radicals have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example as medicaments for the prevention and treatment of type 2 diabetes.
    Type: Grant
    Filed: July 27, 2004
    Date of Patent: May 27, 2008
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Dieter Kadereit, Elisabeth Defossa, Karl Schoenafinger, Thomas Kalbunde, Andreas Herling
  • USE OF SUBSTITUTED CYCLOPROPANE ACID DERIVATIVES FOR PRODUCING DRUGS FOR USE IN THE TREATMENT OF METABOLIC SYNDROME
    Publication number: 20080045590
    Abstract: Disclosed is the use of certain substituted cyclopropane acid derivatives of Formula 1 as defined herein and of their physiologically tolerated salts for treating metabolic syndrome and related disorders.
    Type: Application
    Filed: June 7, 2007
    Publication date: February 21, 2008
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Dieter Kadereit, Siegfried Stengelin, Hubert Heuer, Harm Brummerhop
  • UREA-AND URETHANE-SUBSTITUTED ACYLUREAS, PROCESS FOR THEIR PREPARATION AND THEIR USE
    Publication number: 20080033042
    Abstract: The invention relates to urea- and urethane-substituted acylureas and to their physiologically tolerated salts and physiologically functional derivatives. In particular, the invention relates to the compounds of the formula I wherein the radicals have meanings described herein, and to their physiologically tolerated salts and to processes for their preparation. The compounds are suitable for example as antidiabetics.
    Type: Application
    Filed: August 27, 2007
    Publication date: February 7, 2008
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Elisabeth Defossa, Dieter Kadereit, Thomas Klabunde, Hans-Joerg Burger, Andreas Herling, Karl-Ulrich Wendt, Erich Von Roedern, Karl Schoenafinger
  • Urea- and urethane-substituted acylureas, process for their preparation and their use
    Patent number: 7262220
    Abstract: The invention relates to urea- and urethane-substituted acylureas and to their physiologically tolerated salts and physiologically functional derivatives. In particular, the invention relates to the compounds of the formula I wherein the radicals have meanings described herein, and to their physiologically tolerated salts and to processes for their preparation. The compounds are suitable for example as antidiabetics.
    Type: Grant
    Filed: July 11, 2003
    Date of Patent: August 28, 2007
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Elisabeth Defossa, Dieter Kadereit, Thomas Klabunde, Hans-Joerg Burger, Andreas Herling, Karl-Ulrich Wendt, Erich Von Roedern, Karl Schoenafinger